Endothelin-1, big endothelin-1, and nitric oxide in patients with chronic renal disease and hypertension

✍ Scribed by Ivanka Mikulić; József Petrik; Krešimir Galešić; Željko Romić; Ivana Čepelak; Monika Zeljko-Tomić

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 148 KB
• Volume: 23
• Category: Article
• ISSN: 0887-8013
• DOI: 10.1002/jcla.20324

✦ Synopsis

Abstract

The complex pathogenesis of chronic renal disease (CRD) depends on endothelin (ET) axis (ETs and ET receptors) and nitric oxide (NO) because of their vasoactive effects and their role in general modulation of vascular homeostasis. Various renal cells synthesize ETs and NO that play a significant role in renal hemodynamics as well as in water and salt excretion via urine. ET‐1 is a strong vasoconstrictor. Besides its vasoactive effects, ET‐1 modulates mitosis and apoptosis in a cell type‐dependent manner, and may play an important role in CRD pathogenesis. The aims of this study were to emphasize the role and interactions of ET‐1, Big ET‐1, and NO in CRD. Concentrations of these vasoactive molecules were measured in plasma/serum and/or urine of 57 patients with diabetic nephropathy (subgroup 1), arterial hypertension (subgroup 2) or CRD with chronic renal insufficiency (subgroup 3), and in healthy control subjects (n=18). In comparison with control group, urine concentration of Big ET‐1 was significantly increased (13.13 pmol/L vs. 11.34 pmol/L; P<0.001) in CRD patients, whereas plasma and urine concentrations of ET‐1 did not differ significantly. NO concentrations were also significantly increased in CRD patients (serum, 72.55 µmol/L; P<0.001, and urine 141.74 µmol/L; P<0.05) as compared to control group. Study results indicated that Big ET‐1 and NO could be useful diagnostic parameters in CRD for their diagnostic sensitivity and diagnostic specificity (Big ET‐1 in urine: 56.1 and 88.9%, and NO in serum: 66.7 and 83.3%, respectively). In addition, Big ET‐1 may prove useful in the differential diagnosis of diabetic nephropathy (78.6% diagnostic sensitivity and 88.9% diagnostic specificity). J. Clin. Lab. Anal. 23:347–356, 2009. © 2009 Wiley‐Liss, Inc.